Patents by Inventor Janet Lines

Janet Lines has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vista antagonist and methods of use
    Patent number: 11752189
    Abstract: The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of VISTA. The invention further contemplates therapeutic use of the VISTA antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: September 12, 2023
    Assignees: THE TRUSTEES OF DARTMOUTH COLLEGE, KING'S COLLEGE LONDON
    Inventors: Randolph J. Noelle, Sabrina Ceeraz, Isabelle LeMercier, Elizabeth Nowak, Janet Lines, Li Wang, Mark Spaller
  • VISTA ANTAGONIST AND METHODS OF USE
    Publication number: 20210361736
    Abstract: The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of VISTA. The invention further contemplates therapeutic use of the VISTA antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist.
    Type: Application
    Filed: February 26, 2021
    Publication date: November 25, 2021
    Inventors: Randolph J. NOELLE, Sabrina CEERAZ, Isabelle LEMERCIER, Elizabeth NOWAK, Janet LINES, Li WANG, Mark SPALLER
  • Novel VISTA-Ig constructs and the use of VISTA-Ig for Treatment of Autoimmune, Allergic and Inflammatory Disorders
    Publication number: 20210147521
    Abstract: The present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig), preferably also containing a flexible linker intervening the VISTA and Ig Fc polypeptide. The invention also provides the use of VISTA polypeptides, multimeric VISTA polypeptides, VISTA-conjugates (e.g., VISTA-Ig), and VISTA antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions, especially lupus, multiple sclerosis, psoriasis, psoriatic arthritis, multiple sclerosis, Crohn's disease, inflammatory bowel disease and type 1 or type 2 diabetes.
    Type: Application
    Filed: July 30, 2020
    Publication date: May 20, 2021
    Inventors: Randolph J. Noelle, Sabrina Ceeraz, Isabelle LeMercier, Elizabeth Nowak, Janet Lines
  • VISTA antagonist and methods of use
    Patent number: 10933115
    Abstract: The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of VISTA. The invention further contemplates therapeutic use of the VISTA antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: March 2, 2021
    Assignees: THE TRUSTEES OF DARTMOUTH COLLEGE, KING'S GOLLEGE LONDON
    Inventors: Randolph J. Noelle, Sabrina Ceeraz, Isabelle Lemercier, Elizabeth Nowak, Janet Lines, Li Wang, Mark Spaller
  • VISTA-IG FOR TREATMENT OF AUTOIMMUNE, ALLERGIC AND INFLAMMATORY DISORDERS
    Publication number: 20210032317
    Abstract: The present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig). The invention also provides the use of VISTA polypeptides, multimeric VISTA polypeptides, VISTA-conjugates (e.g., VISTA-Ig), and VISTA antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions.
    Type: Application
    Filed: March 16, 2020
    Publication date: February 4, 2021
    Inventors: Randolph J. Noelle, Sabrina Ceeraz, Isabelle LeMercier, Elizabeth Nowak, Janet Lines
  • VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
    Patent number: 10745467
    Abstract: The present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig). The invention also provides the use of VISTA polypeptides, multimeric VISTA polypeptides, VISTA-conjugates (e.g., VISTA-Ig), and VISTA antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: August 18, 2020
    Assignees: THE TRUSTEES OF DARTMOUTH COLLEGE, KING'S COLLEGE LONDON
    Inventors: Randolph J. Noelle, Sabrina Ceeraz, Isabelle LeMercier, Elizabeth Nowak, Janet Lines
  • VISTA ANTAGONIST AND METHODS OF USE
    Publication number: 20200093902
    Abstract: The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of VISTA. The invention further contemplates therapeutic use of the VISTA antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist.
    Type: Application
    Filed: October 31, 2019
    Publication date: March 26, 2020
    Inventors: Randolph J. NOELLE, Sabrina CEERAZ, Isabelle LeMERCIER, Elizabeth NOWAK, Janet LINES, Li WANG, Mark SPALLER
  • Novel VISTA-Ig constructs and the use of VISTA-Ig for Treatment of Autoimmune, Allergic and Inflammatory Disorders
    Publication number: 20180051070
    Abstract: The present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig), preferably also containing a flexible linker intervening the VISTA and Ig Fc polypeptide. The invention also provides the use of VISTA polypeptides, multimeric VISTA polypeptides, VISTA-conjugates (e.g., VISTA-Ig), and VISTA antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions, especially lupus, multiple sclerosis, psoriasis, psoriatic arthritis, multiple sclerosis, Crohn's disease, inflammatory bowel disease and type 1 or type 2 diabetes.
    Type: Application
    Filed: April 18, 2016
    Publication date: February 22, 2018
    Inventors: Randolph J. Noelle, Sabrina Ceeraz, Isabelle LeMercier, Elizabeth Nowak, Janet Lines
  • VISTA ANTAGONIST AND METHODS OF USE
    Publication number: 20160331803
    Abstract: The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of VISTA. The invention further contemplates therapeutic use of the VISTA antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist.
    Type: Application
    Filed: January 23, 2015
    Publication date: November 17, 2016
    Inventors: Randolph J. NOELLE, Sabrina CEERAZ, Isabelle LEMERCIER, Elizabeth NOWAK, Janet LINES, Li WANG, Mark SPALLER
  • VISTA-Ig for Treatment of Autoimmune, Allergic and Inflammatory Disorders
    Publication number: 20160318999
    Abstract: The present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig). The invention also provides the use of VISTA polypeptides, multimeric VISTA polypeptides, VISTA-conjugates (e.g., VISTA-Ig), and VISTA antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions.
    Type: Application
    Filed: June 24, 2013
    Publication date: November 3, 2016
    Inventors: Randolph J. Noelle, Sabrina Ceeraz, Isabelle LeMercier, Elizabeth Nowak, Janet Lines
  • VISTA Antagonist and Methods of Use
    Publication number: 20150231215
    Abstract: The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of VISTA. The invention further contemplates therapeutic use of the VISTA antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist.
    Type: Application
    Filed: November 6, 2014
    Publication date: August 20, 2015
    Inventors: Randolph J. NOELLE, Sabrina CEERAZ, Isabelle LeMERCIER, Elizabeth NOWAK, Janet LINES, Li WANG, Mark SPALLER
  • Novel VISTA-Ig constructs and the use of VISTA-Ig for Treatment of Autoimmune, Allergic and Inflammatory Disorders
    Publication number: 20140220012
    Abstract: The present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig), preferably also containing a flexible linker intervening the VISTA and Ig Fc polypeptide. The invention also provides the use of VISTA polypeptides, multimeric VISTA polypeptides, VISTA-conjugates (e.g., VISTA-Ig), and VISTA antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions, especially lupus, multiple sclerosis, psoriasis, psoriatic arthritis, multiple sclerosis, Crohn's disease, inflammatory bowel disease and type 1 or type 2 diabetes.
    Type: Application
    Filed: June 24, 2013
    Publication date: August 7, 2014
    Inventors: Randolph J. Noelle, Sabrina Ceeraz, Isabelle LeMercier, Elizabeth Nowak, Janet Lines
  • VISTA-Ig for Treatment of Autoimmune, Allergic and Inflammatory Disorders
    Publication number: 20140056892
    Abstract: The present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig). The invention also provides the use of VISTA polypeptides, multimeric VISTA polypeptides, VISTA-conjugates (e.g., VISTA-Ig), and VISTA antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions.
    Type: Application
    Filed: June 24, 2013
    Publication date: February 27, 2014
    Inventors: Randolph J. Noelle, Sabrina Ceeraz, Isabelle LeMercier, Elizabeth Nowak, Janet Lines